Multidrug-Resistant Tuberculosis Among Patients in Baja California, Mexico, and Hispanic Patients in California

被引:7
|
作者
Bojorquez, Ietza [1 ]
Barnes, Richard F. W. [2 ]
Flood, Jennifer [3 ]
Lopez-Gatell, Hugo [4 ]
Garfein, Richard S. [2 ]
Baecker, Claudia E. [5 ]
Alpuche, Celia [4 ]
Vinetz, Joseph M. [6 ]
Catanzaro, Antonino [7 ]
Kato-Maeda, Midori [8 ]
Rodwell, Timothy C. [2 ]
机构
[1] Colegio Frontera Norte, Dept Populat Studies, Tijuana, Baja California, Mexico
[2] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, La Jolla, CA 92093 USA
[3] Calif Dept Publ Hlth, TB Control Branch, Div Communicable Dis Control, Richmond, CA USA
[4] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico
[5] Inst Epidemiol Diag & Reference, Mexico City, DF, Mexico
[6] Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92093 USA
[7] Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA
[8] Univ Calif San Francisco, Dept Med, Pulm & Crit Care Div, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
SAN-DIEGO COUNTY; MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANCE; UNITED-STATES; EPIDEMIOLOGY;
D O I
10.2105/AJPH.2012.301039
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. We sought to compare prevalence and determinants of multidrug-resistant tuberculosis (MDR-TB) between tuberculosis patients in Baja California, Mexico, and Hispanic patients in California. Methods. Using data from Mexico's National TB Drug Resistance Survey (2008-2009) and California Department of Public Health TB case registry (2004-2009), we assessed differences in MDR-TB prevalence comparing (1) Mexicans in Baja California, (2) Mexico-born Hispanics in California, (3) US-born Hispanics in California, and (4) California Hispanics born elsewhere. Results. MDR-TB prevalence was 2.1% in Baja California patients, 1.6% in Mexico-born California patients, 0.4% in US-born California patients, and 2.7% in Hispanic California patients born elsewhere. In multivariate analysis, previous antituberculosis treatment was associated with MDR-TB (odds ratio [OR] = 6.57; 95% confidence interval [CI] = 3.34, 12.96); Mexico-born TB patients in California (OR = 5.08; 95% CI = 1.19, 21.75) and those born elsewhere (OR = 7.69; 95% CI = 1.71, 34.67) had greater odds of MDR-TB compared with US-born patients (reference category). Conclusions. Hispanic patients born outside the US or Mexico were more likely to have MDR-TB than were those born within these countries. Possible explanations include different levels of exposure to resistant strains and inadequate treatment.
引用
收藏
页码:1301 / 1305
页数:5
相关论文
共 50 条
  • [1] Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
    Katrak, Shereen
    Lowenthal, Phil
    Shen, Richard
    True, Lisa
    Henry, Leslie
    Barry, Pennan
    JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES, 2021, 23
  • [2] Outcome and treatment among patients with multidrug-resistant tuberculosis
    Ramirez Lapausa, Marta
    Pascual Pareja, Jose Francisco
    Amer Perez, Mariam
    Vidal Perez, Jose Luis
    Noguerado Asensio, Arturo
    MEDICINA CLINICA, 2012, 138 (15): : 643 - 649
  • [3] MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITH AIDS
    DIPERRI, G
    VENTO, S
    CAZZADORI, A
    BONORA, S
    CONCIA, E
    ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (13) : 1452 - 1453
  • [4] Comorbidome in multidrug-resistant tuberculosis patients
    Ivanova, Diana
    Borisov, Sergey
    Nikolenko, Nickolay
    Kosenkov, Sergey
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [5] Management of patients with multidrug-resistant tuberculosis
    Lange, C.
    Aarnoutse, R. E.
    Alffenaar, J. W. C.
    Bothamley, G.
    Brinkmann, F.
    Costa, J.
    Chesov, D.
    van Crevel, R.
    Dedicoat, M.
    Dominguez, J.
    Duarte, R.
    Grobbel, H. P.
    Guenther, G.
    Guglielmetti, L.
    Heyckendorf, J.
    Kay, A. W.
    Kirakosyan, O.
    Kirk, O.
    Koczulla, R. A.
    Kudriashov, G. G.
    Kuksa, L.
    van Leth, F.
    Magis-Escurra, C.
    Mandalakas, A. M.
    Molina-Moya, B.
    Peloquin, C. A.
    Reimann, M.
    Rumetshofer, R.
    Schaaf, H. S.
    Schon, T.
    Tiberi, S.
    Valda, J.
    Yablonskii, P. K.
    Dheda, K.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2019, 23 (06) : 645 - 662
  • [6] Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis
    Shin, SY
    Furin, J
    Alcántara, F
    Hyson, A
    Joseph, K
    Sánchez, E
    Rich, M
    CHEST, 2004, 125 (03) : 974 - 980
  • [7] Treatment outcomes among patients with multidrug-resistant tuberculosis Reply
    Orenstein, Evan W.
    Galvani, Alison P.
    LANCET INFECTIOUS DISEASES, 2010, 10 (04): : 215 - 216
  • [8] Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania
    Mollel, Edson W.
    Chilongola, Jaffu O.
    JOURNAL OF TROPICAL MEDICINE, 2017, 2017
  • [9] Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis
    Kempker, Russell R.
    Barth, Aline B.
    Vashakidze, Sergo
    Nikolaishvili, Ketino
    Sabulua, Irina
    Tukvadze, Nestani
    Bablishvili, Nino
    Gogishvili, Shota
    Singh, Ravi Shankar P.
    Guarner, Jeannette
    Derendorf, Hartmut
    Peloquin, Charles A.
    Blumberg, Henry M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3149 - 3155
  • [10] Multidrug-resistant tuberculosis among previously treated patients in the Philippines
    Gler, M. T.
    Macalintal, L. E.
    Raymond, L.
    Guilatco, R.
    Quelapio, M. I. D.
    Tupasi, T. E.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2011, 15 (05) : 652 - 656